Revacept in Symptomatic Carotid Stenosis

Inclusion Criteria: 1. Signed written informed consent 2. Target population * Diagnosis: * Extracranial carotid artery stenosis (diagnosed by vascular duplex ultrasound peak flow or angiography) * Lesions with ≥ 50 % stenosis according to the European Carotid Surgery Trial (ECST) criteria * TIA, amaurosis fugax or stroke within the last 30 days * Age and sex: Men and women aged \> 18 years Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after receiving investigational product in such a manner that the risk of pregnancy is minimised. Exclusion Criteria: 1. Sex and reproductive Status: * WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for up to 4 weeks after receiving investigational product. * Women who are pregnant or breastfeeding * Women with a positive pregnancy test on enrollment or prior to investigational product administration. 2. Target disease exceptions * NIHSS score \> 18 * Recent intracerebral haemorrhage by X-ray computed tomography (CT) or nuclear magnetic resonance (NMR) * Cardiac cause of embolisation (atrial fibrillation or other cardiac source e.g. artificial heart valves) 3. Medical history and concurrent disease * History of hypersensitivity, contraindication or serious adverse reaction to inhibitors of platelet aggregation, hypersensitivity to related drugs (cross-allergy) or to any of the excipients in the study drug * History or evidence of thrombocytopenia (\<30.000/ul), bleeding diathesis or coagulopathy (pathological international normalised ratio (INR) or activated partial thromboplastin time (aPTT)) * Thrombolysis within the last 48 hours * Relevant haemorrhagic transformation as determined by CT, NMR or anamnesis * Oral anticoagulation or dual anti-platelet therapy with aspirin or clopidogrel and other P2Y inhibitors at screening (3 days for dipyridamole extended release; 8 hours for tirofiban/Aggrastat) * Sustained hypertension (systolic BP \> 179 mmHg or diastolic BP \>109 mmHg) * History of severe systemic disease such as terminal carcinoma, renal failure (or current creatinine \> 200 umol/l), cirrhosis, severe dementia, or psychosis * Current severe liver dysfunction (transaminase level greater than 5-fold over upper normal range limit) * Active autoimmune disorder such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis or glomerulonephritis * Known atrial fibrillation or other clinically significant ECG abnormalities (at present)